资产 更改
Agenus USD 226.8M 7.09M 2025-12
Amgen USD 90.59B 445M 2025-12
Anika Therapeutics USD 190.27M 833K 2025-12
Arrowhead Research USD 1.6B 218.89M 2025-12
AstraZeneca USD 114.07B 382M 2025-12
BioMarin Pharmaceutical USD 7.59B 20.85M 2025-12
Bristol-Myers Squibb USD 96.89B 2.21B 2025-09
Celldex Therapeutics USD 582.98M 65.46M 2025-12
Daiichi Sankyo JPY 3.82T 252.52B 2025-12
Eli Lilly USD 112.48B 2.46B 2025-12
Halozyme Therapeutics USD 2.53B 304.09M 2025-12
Heron Therapeutics USD 255.88M 6.93M 2025-12
Intrexon USD 73.16M 77.88M 2024-06
Ionis Pharmaceuticals USD 3.52B 490.91M 2025-12
Karyopharm Therapeutics USD 96.23M 8.65M 2025-09
Ligand Pharmaceuticals USD 1.56B 83.86M 2025-12
MacroGenics USD 256.85M 13.92M 2025-12
Neurocrine Biosciences USD 4.63B 365.8M 2025-12
Pfizer USD 208.73B 2.64B 2025-09
Regeneron Pharmaceuticals USD 40.56B 389.3M 2025-12
Rigel Pharmaceuticals USD 242.53M 35.8M 2025-09
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Ultragenyx Pharmaceutical USD 1.53B 341.56M 2025-12
Veracyte USD 1.41B 38.23M 2025-12